Patents by Inventor Mark Brönstrup
Mark Brönstrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11331371Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: GrantFiled: October 28, 2019Date of Patent: May 17, 2022Assignees: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Patent number: 11236059Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.Type: GrantFiled: August 8, 2018Date of Patent: February 1, 2022Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Philipp Klahn, Mark Broenstrup, Verena Fetz, Wera Collisi, Katrin I Mohr, Stephan Huettel, Werner Tegge
-
Patent number: 11072590Abstract: The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker molecule, a bioactive agent, an activity based probe suitable to monitor the aberrant expression or activity of proteins involved in the initiation and progression of bacterial infection, or a compound useful for bacterial inhibition. In a further aspect, the present invention provides a pharmaceutical composition containing said compound, for example, said pharmaceutical composition is an antibiotic. Additionally, the present invention relates to the use of said compounds in diagnostic methods, in particular, imaging methods including SPEC, PET or MRI. In an embodiment of the present invention, the compound is part of a theranostic composition having both, therapeutic as well as diagnostic activities.Type: GrantFiled: August 18, 2015Date of Patent: July 27, 2021Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Mark Broenstrup, Haiyu Hu, Galina Sergeev, Bushra Rais, Kevin Ferreira, Verena Fetz
-
Patent number: 11034648Abstract: The present invention relates to novel derivatives of cystobactamides of formula (Ib) and the use thereof for the treatment or prophylaxis of bacterial infections.Type: GrantFiled: August 23, 2018Date of Patent: June 15, 2021Assignees: HELMHOLTZ-ZENTRUM FÜR, INFEKTIONSFORSCHUNG GMBHInventors: Giambattista Testolin, Mark Brönstrup, Hans-Peter Prochnow, Jennifer Herrmann, Rolf Müller, Charlotte Grandclaudon, Tim Mollner, Antje Ritter
-
Publication number: 20200239426Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.Type: ApplicationFiled: August 8, 2018Publication date: July 30, 2020Inventors: Philipp KLAHN, Mark BROENSTRUP, Verena FETZ, Wera COLLISI, Katrin I MOHR, Stephan HUETTEL, Werner TEGGE
-
Publication number: 20200216852Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycm.Type: ApplicationFiled: December 19, 2019Publication date: July 9, 2020Inventors: Claus LATTEMANN, Mark BROENSTRUP, Stefan WERNER, Rolf MÜLLER, Kirsten HARMROLS
-
Publication number: 20200190020Abstract: The present invention relates to novel derivatives of cystobactamides of formula (Ib) and the use thereof for the treatment or prophylaxis of bacterial infections.Type: ApplicationFiled: August 23, 2018Publication date: June 18, 2020Inventors: Giambattista Testolin, Mark Brönstrup, Hans-Peter Prochnow, Jennifer Herrmann, Rolf Müller, Charlotte Grandclaudon, Tim Mollner, Antje Ritter
-
Publication number: 20200093888Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: ApplicationFiled: October 28, 2019Publication date: March 26, 2020Applicants: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Patent number: 10550397Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycin.Type: GrantFiled: May 13, 2013Date of Patent: February 4, 2020Assignee: SANOFIInventors: Claus Lattemann, Mark Broenstrup, Stefan Werner, Rolf Müller, Kirsten Harmrols
-
Patent number: 10520488Abstract: A method for determination of the growth rate of biofilm using an electrical impedance analyses is disclosed. The method comprises the steps of: bringing a culture medium fluid in contact to an electrode structure, having biofilm grown within the fluid culture medium with the biofilm arranged in distance to the electrodes structure, so that the fluid culture medium is placed between the growing biofilm and the electrode structure; measuring the impedance of the electrodes structure over a monitoring time, and determining the growth rate of the biofilm as a function of the reduction rate of the impedance values measured on the electrode structure.Type: GrantFiled: December 18, 2015Date of Patent: December 31, 2019Assignee: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Jost Van Duuren, Blanka Karge, Christoph Wittmann, Mark Broenstrup
-
Publication number: 20190046604Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.Type: ApplicationFiled: November 18, 2016Publication date: February 14, 2019Applicants: Helmholtz-Zentrum Für Infektionsforschung GMBH, Medizinische Hochschule Hannover, Twincore, Zentrum Für Experimentelle und Klinische Infektionsforschung GMBHInventors: Mark Brönstrup, Hans-Peter Prochnow, N.V. Suryanarayana Birudukota, Thomas Schulz, Martin Messerle, Thomas Pietschmann, Sibylle Haid, Sebastian Blockus, Christine Laqmani-Goffinet, Sergej Franz, Dominic Howard Banda
-
Publication number: 20170350875Abstract: A method for determination of the growth rate of biofilm (7) using an electrical impedance analyses is disclosed. The method comprises the steps of: bringing a culture medium fluid (3) in contact to an electrode structure (4a, 4b), having biofilm (7) grown within the fluid culture medium (3) with the biofilm (7) arranged in distance to the electrodes structure (4a, 4b), so that the fluid culture medium (3) is placed between the growing biofilm (7) and the electrode structure (4a, 4b); measuring the impedance of the electrodes structure (4a, 4b) over a monitoring time, and determining the growth rate of the biofilm (7) as a function of the reduction rate of the impedance values measured on the electrode structure (4a, 4b).Type: ApplicationFiled: December 18, 2015Publication date: December 7, 2017Applicant: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Jost VAN DUUREN, Blanka KARGE, Christoph WITTMANN, Mark BROENSTRUP
-
Publication number: 20170240582Abstract: The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker molecule, a bioactive agent, an activity based probe suitable to monitor the aberrant expression or activity of proteins involved in the initiation and progression of bacterial infection, or a compound useful for bacterial inhibition. In a further aspect, the present invention provides a pharmaceutical composition containing said compound, for example, said pharmaceutical composition is an antibiotic. Additionally, the present invention relates to the use of said compounds in diagnostic methods, in particular, imaging methods including SPEC, PET or MRI. In an embodiment of the present invention, the compound is part of a theranostic composition having both, therapeutic as well as diagnostic activities.Type: ApplicationFiled: August 18, 2015Publication date: August 24, 2017Inventors: Mark BROENSTRUP, Haiyu HU, Galina SERGEEV, Bushra RAIS, Kevin FERREIRA, Verena FETZ
-
Patent number: 9688645Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.Type: GrantFiled: March 1, 2016Date of Patent: June 27, 2017Assignee: SANOFIInventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
-
Publication number: 20170029436Abstract: The present invention relates to compounds according to general formula (I); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a Th17-associated inflammatory and/or autoimmune disease.Type: ApplicationFiled: April 10, 2015Publication date: February 2, 2017Applicants: Helmoltz-Zentrum für Infektionsforschung GmbH, TWINCORE Zentrum für klinische Infektionsforschung GmbH, TWINCORE Zentrum für klinische Infektionsforschung GmbHInventors: Rolf Mueller, Jochen Huehn, Heinrich Steinmetz, Matthias Keck, Kirsten Harmrolfs, Tim Sparwasser, Matthias Lochner, Amrita Nandan, George Koutsoudakis, Andreas Meyerhans, Juana Diez, Javier Martinez, Mark Brönstrup
-
Publication number: 20160251324Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: March 1, 2016Publication date: September 1, 2016Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER
-
Patent number: 9422566Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.Type: GrantFiled: October 11, 2012Date of Patent: August 23, 2016Assignee: SANOFIInventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
-
Patent number: 9309207Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.Type: GrantFiled: July 28, 2015Date of Patent: April 12, 2016Assignee: SANOFIInventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
-
Publication number: 20160024033Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: July 28, 2015Publication date: January 28, 2016Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER
-
Publication number: 20150274787Abstract: The present invention relates to a method for recombinant production of Labyrinthopeptins and functional derivatives thereof. Moreover, the present invention relates to novel functional derivatives of Labyrinthopeptins.Type: ApplicationFiled: December 19, 2012Publication date: October 1, 2015Inventors: Joachim Wink, Mark Broenstrup, Stefan Bartoschek, Luigi Toti, Roderich Suessmuth, Joanna Krawczyk